Neumora Therapeutics, Inc. (NASDAQ:NMRA) Insider Robert A. Lenz Sells 5,563 Shares

Neumora Therapeutics, Inc. (NASDAQ:NMRA) insider Robert A. Lenz sold 5,563 shares of the firm’s stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $15.01, for a total transaction of $83,500.63. Following the completion of the transaction, the insider now directly owns 322,966 shares in the company, valued at $4,847,719.66. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Neumora Therapeutics Stock Performance

NMRA stock traded up $0.11 during midday trading on Friday, hitting $15.51. 1,069,912 shares of the company’s stock were exchanged, compared to its average volume of 650,216. Neumora Therapeutics, Inc. has a one year low of $8.33 and a one year high of $21.00. The company has a market cap of $2.48 billion and a PE ratio of -6.06. The stock’s fifty day moving average price is $12.20 and its 200-day moving average price is $11.24.

Neumora Therapeutics (NASDAQ:NMRA) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.37) earnings per share for the quarter, meeting the consensus estimate of ($0.37). On average, analysts expect that Neumora Therapeutics, Inc. will post -1.48 EPS for the current year.

Analyst Ratings Changes

A number of analysts have commented on NMRA shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $29.00 target price on shares of Neumora Therapeutics in a report on Wednesday, September 4th. Mizuho initiated coverage on Neumora Therapeutics in a research note on Monday, July 8th. They set an “outperform” rating and a $20.00 price objective for the company. Needham & Company LLC reissued a “buy” rating and issued a $23.00 target price on shares of Neumora Therapeutics in a research note on Thursday, September 12th. Finally, HC Wainwright began coverage on Neumora Therapeutics in a research report on Tuesday, October 1st. They set a “buy” rating and a $30.00 target price for the company. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $22.83.

Institutional Investors Weigh In On Neumora Therapeutics

Several large investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD acquired a new position in Neumora Therapeutics in the 1st quarter worth $10,354,000. Callan Capital LLC boosted its position in shares of Neumora Therapeutics by 222.6% during the second quarter. Callan Capital LLC now owns 661,194 shares of the company’s stock worth $6,500,000 after buying an additional 456,207 shares during the period. Rhumbline Advisers boosted its position in shares of Neumora Therapeutics by 488.3% during the second quarter. Rhumbline Advisers now owns 103,258 shares of the company’s stock worth $1,015,000 after buying an additional 85,706 shares during the period. SG Americas Securities LLC acquired a new stake in Neumora Therapeutics in the 2nd quarter valued at approximately $566,000. Finally, Marshall Wace LLP bought a new stake in Neumora Therapeutics in the 2nd quarter valued at approximately $1,323,000. Institutional investors own 47.65% of the company’s stock.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.